Navigation Links
Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
Date:11/10/2008

TORONTO, Nov. 10 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended September 30, 2008.

Selected Highlights

-------------------

During the first quarter of fiscal 2009 and up to the date of this press release, the Company achieved the following significant milestones:

ELND005 (AZD-103) - Alzheimer's Disease:

- On October 20, 2008, Elan and Transition announced the achievement of

the patient enrollment target for a Phase II clinical study of

ELND005 (AZD-103) in patients with Alzheimer's disease. The study is

a randomized, double-blind, placebo-controlled, dose-ranging, safety

and efficacy study in patients with mild to moderate Alzheimer's

disease. Each patient's planned treatment period is approximately 18

months;

TT-223 - Diabetes:

- On September 11, 2008, Transition dosed the first patient in a Phase

II clinical study of gastrin analogue, TT-223, in patients with type

2 diabetes. The study is a randomized, double-blind, placebo-

controlled, dose-ranging study to evaluate the safety, tolerability

and efficacy of daily TT-223 treatments for 12 weeks with a 6-month

follow-up. Approximately 80 patients with type 2 diabetes are

expected to be enrolled in the study and will receive a daily

treatment of TT-223 in addition to their current regimen of oral

glucose lowering agents (metformin and/or thiazolidinediones);

Drug Discovery Initiatives:

- On August 18, 2008, the Company announced the acquisition of certain

assets and the exclusive rights to selected drug discovery projects

from Forbes Medi-Tech (Re
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Respiratory Leaders Urge Medical Community to Educate Patients Transitioning CFC to HFA Inhalers
2. Transitions Optical to Provide Free Vision Screenings at the American Diabetes Associations Feria de Salud por tu Familia(TM)
3. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
4. Schering-Plough Announces Transition of Animal Health Leadership
5. ACS Signs $27 Million Contract with Alaska to Transition Fiscal Agent Services for State Medicaid Program
6. MidSouth eHealth Alliance to Transition to Commercial Software Solution from Informatics Corporation of America
7. Transition Therapeutics Announces No Material Change
8. Transitions Optical Offers Tips on How to Protect Eyes for Outdoor Sports Fans
9. Transition Therapeutics Announces Executive Management Appointments
10. AGA Medical Announces Management Transition
11. Booth Radiology Associates Chooses IDC To Complete Its Transition To Digital Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... one of two inventors from Miller Place, N.Y. "I specialize in manual therapy, ... discomfort. In addition, it can be used for additional muscle dysfunction throughout the ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and President of ... increase acceptance of the chiropractic field in the military. All too often VA hospitals ... Chiropractic was made available to the VA program over a decade ago, the reality ...
(Date:8/29/2015)... ... ... ProDrop Particles includes over 40 particle backdrops designed for use in ... users can shrink and stretch in the Final Cut Pro X timeline. Choose from ... scale, speed, range, and flare attributes with intuitive controls found in the top-right inspector ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN AMERICA, ... that it will be devoting an entire short segment to the subject of diabetes. ... the globe on a daily basis, but recent advancements in medical science may prove ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a growing ... Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) to ... wound center. , Transitioning wound care management providers can be a complex ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... SUNDAY, Dec. 11 (HealthDay News) -- A drug called ... cell anemia can also help young children with the disease, ... younger than 4 years old who took the medication had ... with fever and need for transfusions, the study found. ...
... study has found that alcohol consumption directly impacts a person,s intention ... drink, the stronger becomes your intention to engage in unsafe sex. ... HIV infection, and it is a main risk factor for the ... to prevent unsafe sex, HIV incidence in most high income countries ...
... Giving low-dose aspirin to patients after they,ve received stronger blood ... odds of redeveloping the clots, a new study finds. ... include both the leg clots known as deep-vein thromboses, or ... pulse, shortness of breath, chest pain and even death. ...
... protein that was a primary mediator of the birth defects caused ... myeloma , says the study,s senior investigator, Keith Stewart, M.B., ... presented the results at the 53rd annual meeting of the ... thalidomide achieved infamy in the early 1960s as the cause of ...
... December 10, 2011) Symptoms improved significantly in adults ... treatment with gene therapy developed by researchers at St. ... be safe in a clinical trial conducted at the ... findings of the six-person study mark the first proof ...
... , FRIDAY, Dec. 9 (HealthDay News) -- Flu vaccination ... to protect your health during the flu season, but too ... often shrug off concerns about the flu, yet every year ... than 200,000 to the hospital and killing thousands," Dr. Thomas ...
Cached Medicine News:Health News:Adult Sickle Cell Drug May Benefit Kids, Too 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 3Health News:Alcohol can lead to unsafe sex: It's official 2Health News:Low-Dose Aspirin After Lung Clot Could Prevent Recurrence 2Health News:Low-Dose Aspirin After Lung Clot Could Prevent Recurrence 3Health News:Mayo Clinic: How patients will respond to immunomodulator therapy for multiple myeloma 2Health News:Gene therapy achieves early success against hereditary bleeding disorder 2Health News:Gene therapy achieves early success against hereditary bleeding disorder 3Health News:Americans Encouraged to Get Flu Vaccine 2
(Date:8/28/2015)... , Aug. 28, 2015 ... and Dr. Ra from Biostar , Published in ... 30% increase of lifespan through multiple IV administration of ... vitality, and life expectancy found , Commercialization within ... have determined the possibility that adult mesenchymal stem cells ...
(Date:8/27/2015)... 2015  The Academy of Managed Care Pharmacy ... (FDA,s) draft guidance and proposed rule that calls ... bear a nonproprietary name with an FDA-designated suffix. ... decision from the FDA on the naming issue ... urging the agency to use the same nonproprietary ...
(Date:8/27/2015)... According to a new market research report "Medical Lifting ... ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End User ... Medical Lifting Sling Market is poised to reach USD 706.0 Million ... of 11.4 % from 2015 to 2020. , ... ables and 65 F igures ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... Provides Tolerable and Effective Symptom Control, ... SHP, Nasdaq:,SHPGY, TSX: SHQ), the global specialty ... study of DAYTRANA(TM) (methylphenidate,transdermal system), the Attention ... provided significant ADHD tolerability,and symptom control improvement ...
... Anti-Tumor Activity of NKTR-102 Associated With Increased ... Tumor Tissue to the Active Metabolite of ... Nektar Therapeutics,(Nasdaq: NKTR ) presented positive ... NKTR-102 (PEG-irinotecan) at the AACR-NCI-EORTC,International Conference in ...
Cached Medicine Technology:Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 2Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 3Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 4Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 5NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 2NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 3NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 4NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 5
Super High Density, multi-frequency, convex array, small footprint transducer for scanning during craniotomies....
... is our High Penetration Steered Linear Peripheral ... 3 to 8 MHz. It is ... Harmonic Detection with 4 different settings to ... vessels. The high color and Doppler sensitivity ...
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer....
HST, multi frequency Side Fire "T intraoperative transducer. A wide field of view is this transducers benefit....
Medicine Products: